Boston Scientific reports above-consensus Q4 results, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Boston Scientific (BSX) PT Raised to $120 at Jefferies
February 5, 2025 2:48 PM ESTJefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $100.00) while maintaining a Buy rating.
The analyst comments "BSX reported 4Q24 sales of $4.56B, +19.5% organic, vs cons $4.42B and EPS of $0.70 +27% vs cons $0.66. BSX introduced '25 guidance... More
Boston Scientific (BSX) PT Raised to $122 at Citi
February 5, 2025 2:06 PM ESTCiti analyst Joanna Wuensch raised the price target on Boston Scientific (NYSE: BSX) to $122.00 (from $107.00) while maintaining a Buy rating.
The analyst commment "BSX delivered another strong quarter meaningfully surpassing consensus, with four of the eight segments delivering double-digit growth, including Electrophysiology sales... More
Boston Scientific (BSX) PT Raised to $120 at BTIG
February 5, 2025 2:00 PM ESTBTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $101.00) while maintaining a Buy rating.
The analyst comments "High-flying BSX reported another strong quarter, posting Q4 revenue of $4.561B (+22.4% rep., +19.5% org.) and adj. EPS of $0.70 (consensus: $4.416B and $0.66), well above its guidance of 14-16% organic sales growth and $0.64-$0.66 adj. EPS. The beat was once again led by Electrophysiology which grew ~172% y/y to $649M (consensus $575M), driven by Farapulse, which surpassed $1B in global revenue in 2024. Watchman grew 20% y/y org. to $413M, above consensus of $406M,... More
